Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced the successful completion of a Phase II clinical study for its Category 1 product candidate, jacktinib tablets, in the treatment of idiopathic pulmonary fibrosis (IPF). The study demonstrated that jacktinib tablets effectively delayed the decline in forced vital capacity (FVC), a key indicator in IPF, compared to a placebo group.
In the trial, patients were randomly assigned to receive either 50mg or 75mg of jacktinib tablets twice daily (Bid) or a placebo. At the 24-week mark, both dose groups of jacktinib showed a statistically significant delay in FVC decline versus the placebo. Additionally, the drug exhibited good tolerability and safety profiles across both dosages.
Jacktinib, a Janus kinase (JAK) inhibitor, is known for its potent inhibitory effects on JAK1, JAK2, JAK3, and TYK2, with particular emphasis on JAK2 and TYK2. This JAK inhibitor is currently under investigation in multiple clinical trials for a range of immunoinflammatory and fibrotic diseases. These include myelofibrosis, severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, idiopathic fibrosis, and moderate to severe plaque psoriasis, among others.- Flcube.com
